Silo Pharma Inc. (NASDAQ: SILO) announced a strategic expansion into artificial intelligence as a second line of business following its acquisition of assets from Qwikagents.ai, a platform designed to deploy autonomous AI agents for tasks including research, content generation, scheduling and workflow automation. The move positions the company to capitalize on a rapidly growing AI agent market projected to reach $47 billion to $53 billion by 2030, according to the press release. The company will retain its focus on biopharmaceutical development, advancing its SPC-15 PTSD program toward an investigational new drug application submission and Phase 1 clinical trials.
The acquisition underscores a dual focus for Silo Pharma: continuing its core biopharmaceutical work while pursuing emerging AI-driven revenue opportunities. The company's therapeutic focus remains on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories, as noted in the release.
The AI agent market is experiencing rapid growth, with projections indicating a substantial increase in value over the next decade. By integrating Qwikagents.ai's autonomous agent capabilities, Silo Pharma aims to leverage artificial intelligence for internal efficiencies and potentially as a revenue-generating service. The acquisition provides the company with a platform that can handle a variety of automated tasks, potentially reducing operational costs and opening new business lines.
For investors, the expansion into AI represents a diversification strategy that may mitigate risks associated with the lengthy and uncertain drug development process. Silo Pharma continues to advance its clinical programs, particularly SPC-15 for PTSD, which targets a significant unmet medical need. The company's ability to generate revenue from AI services could provide financial stability while it pursues regulatory approvals for its drug candidates.
The press release also highlights Silo Pharma's status as a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The company's newsroom provides the latest updates and information regarding SILO at https://ibn.fm/SILO. The full press release regarding the acquisition is available at https://ibn.fm/XJG64.
This strategic move reflects a broader trend of biotech companies exploring artificial intelligence to enhance operations and create new revenue streams. As the AI agent market expands, Silo Pharma's early entry could position it favorably among competitors. The company's continued investment in its biopharmaceutical pipeline ensures that it remains committed to its core mission while exploring innovative technologies.
